



## Fungal Confections in COVID-19 Patients (Literature Review)

**Khairi Jameel Al-Ruaby**

Department of Biology, College of Science, Wasit University, Iraq  
Correspondence author; [Khairi.iraq2009@gmail.com](mailto:Khairi.iraq2009@gmail.com)

ABSTRACT

This article highlight on the Fungal Coinfections in COVID-19 Patients.. Fungal respiratory infections are a major cause of death in immunocompromised persons and are an increasing global health concern. Concerningly, it has been discovered that some individuals with acute respiratory distress syndrome brought on by corona virus disease-19 (COVID-19) are predisposed to airborne fungal co-infections . Common fungal illnesses found associated with COVID-19 infection include Aspergillosis, Candidiasis, Cryptococcosis, and Mucormycosis present a synopsis of these symptoms. Aspergillus species, Candida, Cryptococcus neoformans, and fungus of the Mucorales order, respectively, are the causative agents of these infections. Numerous diseases are caused by fungi in both immunocompetent and immunocompromised people.

**Keywords:**

Covid 19 , Fungal Coinfections, Aspergillosis, immunosuppressive

### Introduction

Among immunocompromised people, fungus is one of the most common infections. A sharp increase in the incidence and mortality rates of fungal infections has been reported among COVID-19 patients, especially those who received immunosuppressive therapies or who have underlying conditions, According to study, viral respiratory disorders like COVID-19 may make a person more susceptible to bacterial, fungal, and viral superinfections and coinfections (1). Superinfection, which happens later, and coinfection, which happens concurrently, cause increased difficulty and complexity in diagnosis since their symptoms overlap, and they consequently impede COVID-19 treatment. The outcomes of such multi-infectious situations are frequently worse than those of either infection alone (2). Infections caused by fungi, for example, frequently share symptoms with COVID-19, such as fever, coughing, and shortness of breath. This makes it challenging to differentiate between the two diseased states. Common fungal illnesses found

associated with COVID-19 infection include Aspergillosis, Candidiasis, Cryptococcosis, and Mucormycosis. A list of such symptoms has been provided. Aspergillus species, Candida, Cryptococcus neoformans, and fungus of the Mucorales order, respectively, are the causative agents of these infections. Numerous diseases are brought on by fungi in both immunocompetent and immunocompromised people (3). The forms of infection and danger differ depending on the pathogenic fungi, which ultimately cause the immune system to become activated. Fungal infections can arise either as a primary or subsequent condition to other diseases (4).

### Aspergillosis infection in COVID-19 Patients

Aspergillosis and the Coronavirus is brought on by the common mold Aspergillus spp., which can be found both indoors and outdoors. The majority of people breathe in Aspergillus spores on a daily basis without getting sick, but those with weakened immune systems or lung conditions are more likely to experience an

active infection. Numerous cases of COVID-19-associated pulmonary aspergillosis (CAPA) have been recorded globally up until the introduction of COVID-19 (5). Patients with COVID-19 who have invasive pulmonary aspergillosis (IPA) had higher mortality rates (6). Each year, invasive fungal infections, particularly those caused by *Aspergillus*, complicate and threaten the lives of millions of people. Numerous infections in humans are caused by *Aspergillus* genera, the most common of which is *Aspergillus fumigatus*. These infections include invasive pulmonary aspergillosis (IPA), chronic pulmonary aspergillosis (CPA), allergic bronchopulmonary aspergillosis (ABPA), chronic rhinosinusitis, fungal sinusitis, and *Aspergillus bronchitis* (7). The most severe form of *Aspergillus* disease, invasive pulmonary aspergillosis (IPA), is linked to high mortality rates and is a common complication in people who have profound immunosuppression, such as those who are receiving hematopoietic stem cell transplants, as well as those who have structural lung damage and are taking systemic corticosteroids for their underlying condition, such as people with chronic obstructive pulmonary disease (8). An intensive care physician who was one of these patients received multiple courses of methylprednisolone. The patient's post-mortem findings were consistent with widespread, invasive aspergillosis and various organ abscesses (9). Secondary bacterial infections have been described in connection with MERS-CoV, another HCoV that also causes severe respiratory infections, but a literature search failed to turn up any evidence of coinfection with *Aspergillus*. The lack of post-mortems performed on these patients, which were typically not done either for religious or cultural reasons or to prevent environmental contamination and the consequent infection of healthcare professionals, must certainly explain this (10). Early reports from China noted the isolation of *Aspergillus* spp. from the respiratory samples (11).

### COVID-19-Associated Invasive Pulmonary Aspergillosis CAPA

According to Schauwvlieghe et al. (2018), influenza-associated pulmonary aspergillosis (IAPA) is a known danger for critically ill patients who have the flu, and the clinical course of COVID-19 exhibits several characteristics in common with severe influenza infection. These include sepsis that causes multiple organ failure, ARDS, lymphopenia, bilateral lung infiltrates, systemic pro-inflammatory cytokine responses, and sepsis (12). Therefore, it stands to reason that individuals with severe COVID-19 may also be vulnerable to invasive aspergillosis. During the SARS-CoV 2003 outbreak, there were case reports of patients who developed SARS-associated invasive aspergillosis after corticosteroid treatment, which is a significant acquired immunological risk factor for IAPA (12). There have been reports of COVID-19 hospital patients taking corticosteroids, and this may increase the risk of CAPA (13).

### Invasive pulmonary aspergillosis complicating COVID-19

*Aspergillus* is an opportunistic fungal infection that can infect immunocompromised hosts and cause deadly illness, including those with hematological malignancies. Due to *Aspergillus*' airborne pathogenic nature, the lungs serve as the body's first line of defense. Invasive pulmonary aspergillosis (IPA) has recently been demonstrated to be related with severe viral lung infections (14). Severe influenza in critically ill patients for example, is complicated by IPA in 7-23% of cases and associated with a case fatality rate of more than 50% (15). The recently discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may cause severe lower respiratory tract infections leading to acute respiratory distress syndrome (ARDS), similar to influenza. This percentage of patients with coronavirus disease 2019 (COVID-19) who develop sepsis with ARDS is considerably high (Wu and McGoogan, 2020).

In severely immunocompromised hosts, *Aspergillus fumigatus* is an opportunistic fungal infection that causes invasive pulmonary aspergillosis (IPA). However, in the past 20 years, cases of IPA in critically ill patients who lack any conventional immunosuppressive factors have been recorded (16). The European Organization for the Research and Treatment of Cancer/Mycosis Study Group Education and Research Consortium's host criteria were not met by these patients. Outlined new standards for identifying "putative" aspergillosis in intensive care unit (ICU) patients who are suspected of having IPA. It's still difficult to identify IPA in immunocompromised people early on. This diagnostic method is significantly more challenging in severely immunocompromised individuals (17), as patients have unusual and non-specific clinical presentations. Corticosteroid use, respiratory diseases, diabetes mellitus, and malnutrition were identified as underlying risk factors for the development of IPA in ICU patients. (18) Particularly among pulmonary illnesses, severe influenza pneumonia was found as an independent risk factor for IPA. In fact, up to 19% of ICU patients who are admitted for severe influenza have IPA (Schauwvlieghe et al., 2018). Because of this, it is very likely that IPA will show up in patients who have ARDS brought on by SARS-CoV-2. According to preliminary reports, patients with severe COVID-19 (CAPA) who were admitted in the ICU had 19–33% more cases of pulmonary aspergillosis (Alanio et al., 2020). The most prevalent filamentous fungal infection seen in immunocompromised people is invasive aspergillosis (IA) (19). Chapter One *Aspergillus fumigatus*, *Aspergillus flavus*, *Aspergillus niger* Literature review and the introduction Although *Aspergillus terreus* is the most common species to cause IA, the bulk of research attribute the majority of cases to *Aspergillus fumigatus* or *A. flavus*. the majority of the time, as the etiological agent. *A. terreus* infections occur anywhere from 3% to 12.5% of the time. Recent in vitro and in vivo studies show that *A. terreus* is more resistant to amphotericin B therapy than *A. fumigatus*, *A. flavus*, and *A. niger* (20). Further laboratory research has demonstrated that novel

antifungal triazoles have considerably increased in vitro and in vivo activity against *A. terreus*, with improved survival in experimental infection.

### **Candidiasis 1 Coinfections 1 Associated 1 With COVID-19**

*Candida* species are one of the most common fungal pathogens causing invasive infections at a global scale (21). Some of the most prevalent yeast species that can be discovered on mucosal surfaces, including the skin and the respiratory, digestive, and urinary systems are *Candida albicans*, *Candida glabrata*, *Candida parapsilosis*, *Candida tropicalis*, and *Candida krusei* (22). Although commensal in the human host, *Candida* species have virulence traits that allow them to invade when an opportunity arises and infect people with a variety of illnesses, especially when the immune system is weak (23). Invasive candidiasis is one of the recognized clinical entities of candidiasis, as are mucosal infections like oropharyngeal or vulvovaginitis candidiasis and superficial infections such skin diseases. The incidence of fungal infections, including candidiasis, has increased worldwide over the past few decades. *Candida albicans* remains the most common causative agent for candidiasis, leading to a range of life-threatening invasive or non-life-threatening superficial conditions (24). During invasive infections, *Candida* have the ability to enter the blood and infect every organ in the host (Pfaller and Diekema, 2007). *Candida* represents the fourth leading cause of nosocomial infections and the third most common cause of catheter-related bloodstream infections, with a mortality rate exceeding 50%. Prolonged Among the most significant factors contributing to invasive yeast infections in COVID-19 patients are hospital stays, usage of broad-spectrum antibiotics, and central venous catheters. According to studies, patients with COVID-19 have a high prevalence of *Candida* infections, making *Candida* species possible pathogens in these patients (25). *Candida* species are present on the skin's mucosal surfaces, in the digestive, respiratory, and urinary tracts, as well as on the skin. Members of the genus *Candida* are the

Most frequently recovered pathogens in ECUs, affect between 6% and 10% of patients. The most common species, *Candida albicans*, is found in 17% of hospitalized ECU patients. Infection with *C. albicans* is linked to considerable morbidity and mortality. Infections by other species of the genus *Candida* are becoming more common, especially among neutropenic patients and patients receiving azole therapy (26).

### Mucormycosis in patients with COVID-19

The Mucorales are significant opportunistic fungi that can infect humans with impaired immune systems and cause mucormycosis. Delay in diagnosis can frequently lead to illness spread, thus an immediate and precise diagnosis is crucial. A significant risk factor for pulmonary mucormycosis is weakened host defense (27). The death rate for mucormycosis is around 46%, while the incidence rate ranges from 0.005 to 1.7 cases per million people. Infarction and necrosis of host tissues are symptoms of infection (28). It is believed that spore inhalation into the paranasal sinuses causes mucormycosis, a secondary infection in susceptible hosts. Mucormycosis is challenging to diagnose, but early detection and treatment are crucial. If there is unilateral facial discomfort or swelling, orbital edema, or proptosis in high-risk patients, mucormycosis should be suspected

(Werthman-Ehrenreich, 2021). Although there are more IPA instances recorded in COVID-19 individuals, mucormycosis cases are uncommon. A case of mucormycosis in a 55-year-old man with COVID-19 was reported. The patient had advanced renal disease and diabetes (29). A COVID-19 patient with pulmonary and systemic mucormycosis who had just undergone a heart transplant. He was diagnosed with cutaneous mucormycosis around three months after receiving a COVID-19 diagnosis (30). Mucormycosis was discovered in a 60-year-old COVID-19 patient who was admitted to the hospital after exhibiting acute dyspnea, pyrexia, tachypnea, and generalized malaise for three days.

Additionally, a 51-year-old man developed pulmonary mucormycosis. These cases illustrate the challenges associated with making a diagnosis of mucormycosis and the need of doing histology testing to enable early detection and treatment of the condition (31).

### Conclusion

It can be concluded notwithstanding the significant illness SARS-CoV-2 caused in many patients, there aren't many invasive mycoses, which is likely because these individuals only had a small number of bronchoscopies and necropsies done because of the high danger of aerosol generation. However, it should be preferable to start antifungal therapy as soon as possible given the presence of fungal markers in clinically relevant specimens, with the exception of *Candida* colonization of the bronchioles.

### Reference

1. Brown, G. D., D. W. Denning, N. A. Gow, S. M. Levitz, M. G. Netea and T. C. White (2012). "Hidden killers: human fungal infections." *Science translational medicine* 4(165): 165rv113-165rv113.
2. Hallen-Adams, H. E. and M. J. Suhr (2017). "Fungi in the healthy human gastrointestinal tract." *Virulence* 8(3): 352-358.
3. Rolling, T., T. M. Hohl and B. Zhai (2020). "Minority report: The intestinal mycobiota in systemic infections." *Current opinion in microbiology* 56: 1-6.
4. Bongomin, F., S. Gago, R. O. Oladele and D. W. Denning (2017). "Global and multi-national prevalence of fungal diseases—estimate precision." *Journal of fungi* 3(4): 57.
5. Achkar, J. M. and B. C. Fries (2010). "Candida infections of the genitourinary tract." *Clinical microbiology reviews* 23(2): 253-273.
6. Pfaller, M. A. and D. Diekema (2007). "Epidemiology of invasive candidiasis: a persistent public health problem." *Clinical microbiology reviews* 20(1): 133-163.

7. Bouza, E., J. Guinea and M. Guembe (2015). "The role of antifungals against *Candida* biofilm in catheter-related candidemia." *Antibiotics* 4(1): 1-17.
8. Heard KL, Hughes S, Mughal N, et al (2020). COVID-19 and fungal superinfection. *Lancet Microbe.*; 1: e107. [https://doi.org/10.1016/S2666-5247\(20\)30065-3](https://doi.org/10.1016/S2666-5247(20)30065-3)
9. Arastehfar A, Carvalho A, Nguyen MH, et al (2020). COVID-19 associated candidiasis (CAC): An underestimated complication in the absence of immunological predispositions? *J fungi (Basel).*; 6: 211. <https://doi.org/10.3390/jof6040211>
10. Bajpai VK, Khan I, Shukla S, et al(2019). Invasive fungal infections and their epidemiology: Measures in the clinical scenario. *Biotechnol Bioprocess Eng.*; 24: 436-444. [https://doi.org/10.1007/S0140-6736\(20\)30211-7](https://doi.org/10.1007/S0140-6736(20)30211-7)
11. Akeem, A. A., Ejikeme, U. C., & Okarafor, E. U. (2012). Antibacterial potentials of the ethanolic extract of the stem bark of *Combretum micranthum* G. Don and its fractions. *Journal of Plant Studies*, 1(2), 75.
12. Brooks, M. L., D'antonio, C. M., Richardson, D. M., Grace, J. B., Keeley, J. E., DiTomaso, J. M., ... & Pyke, D. (2004). Effects of invasive alien plants on fire regimes. *BioScience*, 54(7), 677-688.
13. Ganguly, A., Sharma, S., Papakonstantinou, P., & Hamilton, J. (2011). Probing the thermal deoxygenation of graphene oxide using high-resolution in situ X-ray-based spectroscopies. *The Journal of Physical Chemistry C*, 115(34), 17009-17019.
14. Hoyer, L. L., & Cota, E. (2016). *Candida albicans* Agglutinin-Like Sequence (Als) Family Vignettes: A Review of Als Protein Structure and Function. *Frontiers in microbiology*, 7, 280.
15. Zhang H and Zhu A. Emerging invasive fungal infections (2020): Clinical features and controversies in diagnosis and treatment processes. *Infect Drug Resist.*; 13: 607-615. <https://doi.org/10.2147/IDR.S237815>
16. Nadeem SG, Hakim ST, Kazm SU (2010). Use chromoagar candida medium for the presumptive identification of *Candida* species directly from clinical specimens in resource - limited setting. *Libyan J Med* 5.
17. Campbell Ck, Holmes AD, Davery KG K.G., Szekely A. and Warnock D.W (1998). Comparison of a new chromogenic agar with germ tube method for presumptive identification of *Candida albicans*. *Eur. J. Clin. Microbiol. Infect. Dis.* 17:367-368.
18. Yang, Y. (2003). Virulence factors of *Candida* species. *Jouranal Microbiol Immunol Infect.* 36: 223-228.
19. Daniel FQ Smith, D., & Casadevall, A. (2021). Fungal immunity and pathogenesis in mammals versus the invertebrate model organism *Galleria mellonella*. *Pathogens and disease*, 79(3), ftab013.
20. Hube, B., Sanglard, D., Odds, F. C., Hess, D., Monod, M., Schäfer, W., ... & Gow, N. A. (1997). Disruption of each of the secreted aspartyl proteinase genes SAP1, SAP2, and SAP3 of *Candida albicans* attenuates virulence. *Infection and immunity*, 65(9), 3529-3538.
21. Modrzewska, B., & Kurnatowski, P. (2015). Adherence of *Candida* sp. to host tissues and cells as one of its pathogenicity features. *Annals of parasitology*, 61(1).
22. Apostolopoulou, A., Z. Esquer Garrigos, P. Vijayvargiya, A. H. Lerner and D. Farmakiotis (2020). "Invasive pulmonary aspergillosis in patients with SARS-CoV-2 infection: a systematic review of the literature." *Diagnostics* 10(10): 807.
23. Brown, G. D., D. W. Denning, N. A. Gow, S. M. Levitz, M. G. Netea and T. C. White (2012). "Hidden killers: human fungal infections." *Science translational medicine* 4(165): 165rv113-165rv113.
24. Li, E., J. M. Knight, Y. Wu, A. Luong, A. Rodriguez, F. Kheradmand and D. B.

- Corry (2019). "Airway mycosis in allergic airway disease." *Advances in immunology* 142: 85-140.
25. Kosmidis, C. and D. W. Denning (2015). "The clinical spectrum of pulmonary aspergillosis." *Thorax* 70(3): 270-277.
26. Thompson Iii, G. R., O. A. Cornely, P. G. Pappas, T. F. Patterson, M. Hoenigl, J. D. Jenks, C. J. Clancy and M. H. Nguyen (2020). *Invasive aspergillosis as an under-recognized superinfection in COVID-19*. Open forum infectious diseases, Oxford University Press US.
27. Wang, H.-j., Y.-q. Ding, J. Xu, X. Li, X.-f. Li, L. Yang, W.-l. Zhang, J. Geng, H. Shen and J.-j. Cai (2004). "Death of a SARS case from secondary aspergillus infection." *Chinese medical journal* 117(08): 1278-1280.
28. Wang, H., Y. Ding, X. Li, L. Yang, W. Zhang and W. Kang (2003). "Fatal aspergillosis in a patient with SARS who was treated with corticosteroids." *New England Journal of Medicine* 349(5): 507-508.
29. Arabi, Y. M., A. M. Deeb, F. Al-Hameed, Y. Mandourah, G. A. Almekhlafi, A. A. Sindi, A. Al-Omari, S. Shalhoub, A. Mady and B. Alraddadi (2019). "Macrolides in critically ill patients with Middle East Respiratory Syndrome." *International Journal of Infectious Diseases* 81: 184-190.
30. Memish, Z. A., S. Perlman, M. D. Van Kerkhove and A. Zumla (2020). "Middle East respiratory syndrome." *The Lancet* 395(10229): 1063-1077.
31. Chen, X., B. Liao, L. Cheng, X. Peng, X. Xu, Y. Li, T. Hu, J. Li, X. Zhou and B. Ren (2020). "The microbial coinfection in COVID-19." *Applied microbiology and biotechnology* 104(18): 7777-7785.